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MObjectives:Modified ultrafiltration is a technique after cardiopulmonary bypass whereby blood withdrawn from
the aortic cannula is passed across a semipermeable membrane to hemoconcentrate. Unblinded trials have sug-
gested that modified ultrafiltration is efficacious for blood conservation. The objective of this trial was to assess
the feasibility of a model testing modified ultrafiltration in which all members of the surgical team were blinded to
the intervention.
Methods: Patients (<65 kg) undergoing procedures involving cardiopulmonary bypass were randomized to un-
dergo either modified ultrafiltration (n¼ 29) or sham (circulation without an interposed filter, n¼ 36) for 15 min-
utes. The circuit was shielded from all members of the team except the perfusionist. A questionnaire was
administered to determine the blinding success.
Results: Modified ultrafiltration resulted in a removal of 1000 251 mL of fluid and a reduction in the pump
balance (1025 807 vs 1804 838; P< .001) with an increase in hemoglobin immediately after intervention
(increase of 7.7 8.8 g/L in modified ultrafiltration vs 3.8 5.1 g/L in sham; P¼ .04). Introduction or increase
in dose of vasopressors was more frequent in the modified ultrafiltration group (52% vs 28%; P¼ .048). Differ-
ences in red cell transfusion rates between groups did not reach statistical significance (P¼ .59). Blinding was
successful for the anesthetist (blinding index 0.13 [95% confidence interval, 0.11–0.38] and the intensivist (blind-
ing index, 0.09 [95% confidence interval, 0.14–0.31]) but not for the surgeon (blinding index, 0.24 [95% con-
fidence interval, 0.05–0.42]). The compliance rate for the transfusion protocol was greater than 90%.
Conclusions: Modified ultrafiltration was effective for hemoconcentration after cardiopulmonary bypass in pa-
tients of low body weight, but it is associated with an increased need for vasopressor support. The anesthetist and
intensivist were successfully blinded to the intervention. (J Thorac Cardiovasc Surg 2010;139:701-6)Cardiac surgery is one of the leading consumers of blood
products and it will likely remain so for the foreseeable fu-
ture. Intraoperative and postoperative blood losses are pre-
dictable contributors to this problem. A less commonly
recognized factor is the effect of hemodilution of the patient
by the pump prime of cardiopulmonary bypass (CPB). Thise Division of Cardiac Surgery,a University of Ottawa Heart Institute, Ottawa,
io; Division of Cardiac Surgery,b Queen’s University, Kingston, Kingston,
io; Division of Cardiac Surgery,c Royal Victoria Hospital, Montreal, Quebec;
rtment of Epidemiology and Community Medicine,d University of Ottawa,
a, Ontario; Division of Cardiac Anaesthesia,e University of Ottawa Heart Insti-
Ottowa, Ontario; Division of Perfusion,f University of Ottawa Heart Institute,
a, Ontario; and Department of Medicine,g University of Ottawa, Ottowa,
io, Canada.
ures: None.
dy was funded by grant NA 5565 from the Heart and Stroke Foundation of
io.
d for publication July 13, 2009; revisions received Nov 10, 2009; accepted for
cation Nov 23, 2009.
for reprints: Fraser D. Rubens, MD, MSc, FRCSC, Professor of Surgery, Uni-
y of Ottawa Heart Institute, 40 Ruskin St, Ottawa, Ontario K1Y 4W7, Canada
ail: frubens@ottawaheart.ca).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2009.11.056
The Journal of Thoracic and Cahemodilution is especially pronounced in patients of low
body weight owing to their lower circulatory volume.
Several strategies have been advocated to minimize the
impact of hemodilution, including retrograde autologous
priming, forced diuresis, and ultrafiltration. This latter tech-
nology involves passing the blood across a semipermeable
membrane and using a pressure gradient to remove exces-
sive fluid. The resulting hemoconcentration may improve
coagulation owing to the higher hematocrit1–3 and by the
concentration of coagulation factors.1,2 Low molecular
weight components, which may include cytokines and
toxins, are also removed owing to the membrane pore size,
thus potentially decreasing perioperative inflammation.4,5
Conventional ultrafiltration involves the interposition of
the filter device in series within the CPB circuit. However,
solute removal can only be achieved while the patient is still
supported by CPB; thus, to remove more fluid, CPB times
must be prolonged. On the other hand, with modified ultra-
filtration (MUF), fluid removal occurs after coming off
CPB. The cannulas are left in the ascending aorta and the
right atrium. Fluid is withdrawn from the aortic line andrdiovascular Surgery c Volume 139, Number 3 701
Abbreviations and Acronyms
BI ¼ blinding index
CPB ¼ cardiopulmonary bypass
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Mpassed through the filter device, with the hemoconcentrated
product returned through a side port on the venous cannula.
When the intervention is completed, the cannulas are re-
moved and heparin is reversed.
Pediatric cardiac surgeons have long espoused the bene-
fits of this technology. Several groups have also studied
this approach in adult cardiac surgery, and their data suggest
that this technology may be successful as a blood conserva-
tion strategy.3,6,7 There are several limitations of the previ-
ous trials that may explain why MUF has not been widely
used despite these positive findings. First, none of these tri-
als was blinded and thus bias may have affected transfusion
and other treatment decisions. Second, inasmuch as this pro-
cedure is somewhat inconvenient, the magnitude of the ben-
efit demonstrated may not have been sufficient to influence
current practice. The trials may have been compromised in
their design by the failure to target this technology in pa-
tients who are both at high risk for transfusion and most
likely to benefit from hemoconcentration after CPB, such
as those patients with low body weight. Therefore, a defini-
tive trial that would influence practice would include blind-
ing of the intervention and targeting the strategy to the
highest risk population. Before this trial was undertaken,
a pilot trial was completed to (1) determine the success of in-
traoperative blinding of the intervention, (2) determine the
compliance to the intervention (ie, how often randomized
patients can proceed to the intervention and compliance
with transfusion protocols), (3) determine issues in screen-
ing, recruitment, and safety, and (4) collect data to inform
sample size calculation and hypothesis generation.
We hypothesized that whereas the intensivist should be
easily blinded, blinding of the surgeon may be more difficult
and the anesthesiologist even more so. If all are successfully
blinded (>85% success), in a definitive trial we would pro-
pose to use the current planned intervention. If we are unable
to blind the anesthesiologist, decisions for transfusion would
be made by the surgeon. If neither the surgeon nor the anes-
thesiologist can be successfully blinded, this will be impor-
tant information that would render this aspect of the model
‘‘unblindable’’; thus, in the definitive trial, there would be
no reason to use a sham circuit.METHODS
We conducted a prospective, multicenter, randomized controlled trial in
the Ottawa Heart Institute, the Kingston General Hospital (1 surgeon), and
the Royal Victoria Hospital, Montreal (1 surgeon) between August 2006
and January 2009. The study protocol was approved by the human research702 The Journal of Thoracic and Cardiovascular Surgethics board at each center and written informed consent was obtained from
all patients. Eligible patients included those with weight of 65 kg or less or
body surface area less than 1.7 m2. Patients were excluded for the following
reasons: emergency surgery, off-pump surgery, abciximab use within 7 days
of surgery, inability to obtain consent, age less than 18 years, surgeon re-
fusal, preoperative hemoglobin level less than 100 g/dL, preoperative he-
modialysis, and refusal to accept blood products.
A narcotic-based anesthetic was used. Tranexamic acid (a 1-g bolus after
induction and a 2.0–mg $ kg1 $ h1 intraoperative infusion) was adminis-
tered to all study patients. Antiplatelet and antithrombotic medication was
stopped before surgery according to best practice. After sternotomy, patients
were given heparin to achieve an activated clotting time greater than 400
seconds. CPB was conducted with a roller pump, a membrane oxygenator
(COBE CML Duo; COBE Cardiovascular Inc, Arvada, Colo), a 43-mm ar-
terial filter (COBE Sentry with PrimeGard), a closed venous reservoir bag,
ascending aortic cannula, and 2-stage or double venous cannula return. All
of the pumps were primed with 1300 mL of Ringer lactate. Bypass flows
were maintained at 2.4 to 3.2 L $ m2 $ min1. The heart was arrested
with antegrade cold blood cardioplegic solution. During cardiac anoxia,
the body temperature was reduced to a systemic temperature of 34C, and
at the completion of the procedure patients were rewarmed, with care taken
to never exceed 37C (nasopharyngeal).
Two-way stopcocks were attached to the arterial and venous cannulas.
Treatment was randomly assigned and the intervention was commenced
once the patientwas off CPB in a stable state and the surgeonhadverified con-
trol of surgical bleeding such that protaminewould normally be administered.
The venous linewas then drained, as is routine, to empty all blood into the res-
ervoir in both groups. The inflow tubing for the intervention circuit was then
passed up to the operating site with the inlet attached to the stopcock on the
arterial line. After the tubing had been de-aired, the outlet was attached to
a stopcock on the venous cannula in the right atrium and a clamp was placed
distally such that all reinfusion occurred into the right atrium. In the test
(MUF) group (n¼ 29), suction (150 mm Hg) was applied to an interposed
hemofilter (UF 70; Terumo Inc, Tokyo, Japan). This hemofilter was chosen
because it provides the most rapid rate of filtration among current commer-
cially available devices.8 In the control group (sham; n¼ 36), the circuit
was identical with the exception that there was no interposed filter and
sham flowwas kept at 200 mL/min. During the intervention, the perfusionist
maintained a stable mean blood pressure with a target range within 10% of
starting mean blood pressure by slow readministration of the pump reservoir
volume through the arterial line.When the pump reservoirwas empty, the car-
diotomy reservoir (above the pump reservoir) could no longer be used for
sucker blood owing to standard technical design. Thus, further mediastinal
drainage was transferred to a blood collection device (eg, Atrium device;
Atrium Medical Corporation, Hudson, NH). Autotransfusion (after prot-
amine) was the same for control and experimental groups according to each
institution’s practice. The intervention was continued for 15 minutes in both
groups. In the test group, if itwas determinedby theperfusionist that no further
volume could be removedbefore the target time, suctionwas discontinued and
circuit flow was maintained at 200 mL/min. In both groups, at the end of the
intervention, the venous cannulas were removed, protamine was adminis-
tered, and residual pump volume was infused slowly as per standard practice.
Objectives of the Study
The objectives of the study were as follows:
1. To determine the success of blinding
2. To determine the compliance rate of the clinical model
3. To refine the ascertainment of outcomes andobtain estimates of event rates.Study Outcomes
We proposed a priori that the most important outcome derived from this
pilot project was related to the success of intraoperative blinding. Blinding
was measured using a blinding index (BI) as described by Bang, Ni, andery c March 2010
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MDavis.9 The BI proposed is scaled to an interval of1 to 1, with 1 being com-
plete lack of blinding, 0 being consistent with perfect blinding, and1 indi-
cating opposite guessing, which may be related to unblinding. If a 1-sided
95% confidence limit of the BI does not include 0, the treatment arm is
deemed to fail to achieve blinding.
The BI was ascertained on the basis of a questionnaire administered to
the anesthesiologist and surgeon after each operation and to the intensivist
after 24 hours in the intensive care unit. The questionnaire offered 5 levels
of response, based on their perception of the treatment allocation to which
they think the patient was assigned:
Code 1: ‘‘Strongly believe the treatment was MUF.’’
Code 2: ‘‘Somewhat believe the treatment was MUF.’’
Code 3: ‘‘Somewhat believe the treatment was sham.’’
Code 4: ‘‘Strongly believe the treatment was sham.’’
Code 5: ‘‘Don’t know.’’
Individuals who decline an opinion (‘‘don’t know’’) were subsequently
asked to choose a treatment allocation anyway for a separate analysis. Com-
pliance was measured by the frequency with which randomized patients
proceed to the intervention as well as the compliance with the postinterven-
tion transfusion protocol.
Sample size
The sample size calculation was based on the primary outcome regarding
the success of blinding. To determine the sample size for the present trial, we
calculated the SD of the BI from an example given by Bang, Ni, and Davis9
based on data from a cholesterol lowering trial.
Randomization–Allocation Concealment
Randomization was done in blocks, with sizes ranging from 4 to 8 and
with the block size unknown to the investigators. The randomization pro-
cess consisted of a computer-generated random listing of treatment alloca-
tions, stratified by center. Treatment was assigned by a telephone call made
to the central office in Ottawa just before the operation to enable the perfu-
sionist to prepare the shielded sham or MUF circuits.
Blinding (Masking)
All members of the surgical team except the perfusionist (who did not
make transfusion decisions) were blinded to treatment allocation. A shield
was placed to obscure the pertinent part of the ultrafiltration or ‘‘sham’’ cir-
cuit from the surgeon and the anesthesiologist. Flow was maintained
through the ‘‘sham’’ circuit at 200 mL/min during the intervention so that
the visible circuits appear the same. The return tubing was also wrapped
in paper tape to blind the surgeon with regard to the degree of oxygenation
of the blood (during MUF, oxygen is extracted from the returning blood;
thus it is darker than the sham circuit).
The perfusionist recorded the hemoglobin level at the end of the interven-
tion and informed the anesthesiologist and the surgeon as to whether it was
above or below 70 g/L only. If necessary, the anesthesiologist could request
to be unblinded to the actual value if oxygen delivery was still inadequate
(eg, presence of a base deficit>5 mmol/L or a cardiac index<2 L $ min1 $
m2) such that hemoglobin levels needed to bemanipulated or in case of active
bleeding that could not be managed in a blinded fashion. Transfusions were
given in the intensive care unit with the same threshold; however, the intensiv-
ist (although blinded to treatment group) would not be blinded to the actual he-
moglobin or hematocrit result. The study coordinator in all cases recorded the
indication for the transfusion after consultation with the attending physician.
Statistical Methods
Continuous data are presented as mean  standard deviation for nor-
mally distributed data and median (interquartile range) for nonnormally dis-
tributed data. Continuous variables were compared by a 2-tailed Student tThe Journal of Thoracic and Catest for normally distributed data and Wilcoxon rank sum test for nonnor-
mally distributed data. Categorical variables were compared by the c2 test
or Fisher’s exact test when the cell count in any one cell was less than 5.
Statistical analyses were performed with SAS version 9.1 (SAS Institute
Inc, Cary, NC). The primary end point of blinding index was calculated
as previously described by Bang, Ni, and Davis.9RESULTS
Patient Population and Study Intervention
Patient flow during screening, recruitment, and randomi-
zation is depicted in Figure 1. Demographics of the patients
randomized (Table 1) and hematologic, hemodynamic, and
perfusion data (Table 2) were similar. Analysis was by in-
tent-to-treat. The intraoperative intervention was success-
fully implemented in all patients. MUF was used to
remove an average of 1000 21 mL of fluid in the treated
group, resulting in a significant difference in the net fluid ad-
ministered at the end of CPB (corrected pump balance) be-
tween groups (1804 838 vs 1025 807 mL, sham vs
MUF; P< .001). MUF also resulted in a greater increase
in hematocrit (0.011 0.015 vs 0.024 0.026, sham vs
MUF; P¼ .03) and hemoglobin levels (3.8 5.1 g/L vs
7.7 8.8 g/L, sham vs MUF; P¼ .04). No adverse events
were associated with either intervention.Clinical Outcomes
There was no significant difference in the units of red
blood cells transfusioned after intervention between groups
(2.6 4.3 vs 2.0 1.73 units/patient, sham vs MUF;
P¼ .59). There was no difference in the transfusion rates
when patients who had surgical bleeding were removed
from the calculation (data not shown). The proportion of pa-
tients transfused after the intervention was 74% in the entire
cohort (67% sham, 83% MUF; P¼ .14). Overall blood
product use, including packed red cells, plasma, and plate-
lets, was also similar between groups (6.8 11.6 vs
5.5 7.3 units/patient, sham vs MUF; P¼ .6). Postopera-
tively, there was no significant difference in hemoglobin
levels between groups (91 12 vs. 85 14 g/L, sham vs
MUF; P¼ .12). Compliance with the transfusion protocol
was 91% by the anesthesiologists intraoperatively, 90%
in the intensive care unit, and 100% thereafter until patient
discharge. Five patients in the study required reopening ow-
ing to bleeding or tamponade (MUF¼ 3, SHAM¼ 2).
There was no difference in chest tube output between the
2 groups (712 517 vs 579 332 mL/12 hours, sham vs
MUF; P¼ .21).
Fifteenminutes after intervention, cardiac indexwas lower
in the MUF group than in the sham group (1.9 0.4 vs
2.3 0.5 L $ min1 $ m2; P¼ .004). Furthermore, a larger
proportion of MUF patients had vasopressors started or in-
creased in dosage in the intensive care unit (52% vs 28%;
P¼ .048). The total duration of vasopressor use also tended
to be higher in the MUF patients (12.6 25.5 vsrdiovascular Surgery c Volume 139, Number 3 703
Consort Flowchart – TRAM Trial
Assessed for eligibility 
(n=2817)
Excluded 
(n=2741)
Not meeting inclusion criteria 
(n= 2215) 
Refused to participate
(n=58)
Other reasons
(n= 468) 
Lost to follow-up (n=0)
Allocated to SHAM 
(n=40)
Received allocated intervention 
(n=36)
Did not receive allocated
intervention
(n= 4) 
Reasons 
Instability (1) 
Technical (3) 
Analyzed (n=36) 
Allocation 
Analysis 
Follow-Up 
Enrollment
Randomized 
Analyzed (n=29) 
Lost to follow-up (n=0)
Allocated to MUF
(n=36)
Received allocated intervention 
(n=29)
Did not receive allocated intervention 
(n=7)
Reasons
Conversion OPCAB (1) 
Instability (2) 
Technical (4) 
FIGURE 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of patient flow. MUF,Modified ultrafiltration group; SHAM, control group;
OPCAB, off-pump coronary artery bypass grafting; TRAM, transfusion reduction and modified ultrafiltration.
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M5.2 11.1 hours; P¼ .054). There was no in-hospital mor-
tality, and length of hospital stay was similar between groups
(9.6 9.8 vs 8.9 5.6 days, sham vs MUF; P¼ .71).
Assessment of Blinding
The BI for the surgeon in the MUF group was 0.034
(95% confidence interval [CI], 0.199 to 0.268; P >
.05). In the sham group, the BI for the surgeon was
0.229 (95% CI, 0.052 to 0.406; P < .05). The BI for
the anesthesiologist in the MUF group was 0.138 (95%
CI,0.112 to 0.388; P> .05). The BI in the sham group
was 0.028 (95% CI, 0.191 to 0.247; P> .05). The BI
for the intensivist was 0.091 (95% CI, 0.143 to 0.325;
P> .05) in the MUF group and 0.083 (95% CI, 0.132
to 0.298; P> .05) in the sham group.704 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
In this pilot trial assessing the feasibility of a randomized
double-blind controlled trial comparing MUF and sham cir-
cuits in cardiac surgery, the efficacy of blinding of the
surgeon, the anesthesiologist, and the intensivist was
successfully tested. For the surgeon, there was insufficient
evidence to show unblinding in the MUF group, but there
was a significant excess of correct guesses in the sham
group, such that one can determine that the surgeon could
not be blinded. For the anesthesiologist, there was an excess
of correct guesses in the MUF group, but this was not statis-
tically significant (P>.05), and in the sham group, there was
insufficient evidence to confirm unblinding (P<.05). There
was no significant evidence to confirm unblinding in the in-
tensivist. Finally, there was excellent (>90%) complianceery c March 2010
TABLE 1. Patient demographics
MUF Sham P value
Age (y) 66.3 13.1 71.1 10.1 .11
Sex (% female) 65.5 77.8 .27
BSA 2.21 2.08 2.47 4.19 .06
ASA (%) 83.7 61.1 .06
Clopidogrel (%) 27.6 11.1 .09
Heparin 6.9 8.3 .83
Low molecular weight heparin (%) 6.9 2.8 .43
CCS class III or IV (n) 41 25 .16
NYHA class III or IV (n) 21 25 .68
Abnormal LV function (class II) 34 17 .1
Left main (%) 14 17 .75
Diabetes (%) 24 8.3 .08
Hypertension (%) 55 55 .98
History of MI (%) 21 25 .68
Hypercholesterolemia (%) 45 44 .98
Smoker (%) 38 25 .26
MUF, Modified ultrafiltration; BSA, body surface area; ASA, acetylsalicylic acid use
within 7 days of surgery; CCS, Canadian Cardiovascular Society (angina class);
NYHA, New York Heart Association (congestive heart failure class); LV, left ventric-
ular; MI, myocardial infarction
TABLE 2. Demographics; baseline hematology, and bypass indices
MUF Sham P value
Preoperative hemoglobin (g/dL) 129 17 136 11 .04
Preoperative hematocrit (%) 0.38 0.05 0.40 0.03 .12
Preintervention hemoglobin (g/dL) 84 13 86 11 .39
Platelets (103/mm3) 263 90 256 69 .73
International normalized ratio 1.0 0.1 1.2 0.6 .48
aPTT (s) 29.5 7.8 32.4 21.9 .47
Creatinine (mmol/L) 83 22 82 20 .97
CI at induction (L $ min1 $ m2) 1.96 0.37 2.16 0.71 .46
Anesthesia volume (mL) 1750 1005 1599 834 .55
Pump time (mm) 88 29 95 33 .38
Crossclamp time (mm) 65 23 67 21 .69
Lowest hematocrit on CPB (%) 0.24 0.04 0.24 0.03 .77
Pump balance (mL) 2025 884 1805 838 .31
Inotropes to come off CPB (%) 28 17 .29
MUF,Modified ultrafiltration; aPTT, activated partial thromboplastin time;CI, cardiac
index; CPB, cardiopulmonary bypass.
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Mwith regard to the transfusion protocol by the anesthesiolo-
gist after the intervention as well as by the intensivist in
the first 24 hours after surgery.
As expected, when patients underwent MUF, they experi-
enced a significant increase in their hematocrit value, which
was associated with a significant decrease in their corrected
pump balance. The group that underwent the intervention,
however, was more likely to require vasopressor support
or to have their inotropes increased within the first 24 hours
after the operation. This may be related to uncompensated
hypovolemia, and it would be valuable to measure this in
further studies. There was no statistically significant differ-
ence in the exposure to transfusion products between the
groups undergoing MUF or Treatment Response Assess-
ment Method, but this trial was not powered to detect this
difference as a primary outcome.
MUF has been proposed as an attractive blood conserva-
tion technology.7 It is a relatively inexpensive means to re-
move excessive crystalloid in patients undergoing CPB,
and we hypothesized that its potential positive effects would
be more easily demonstrated in small patients who are at
highest risk of hemodilution. In the total population studied
in this trial, more than 80% of patients are exposed to blood
products. It is also of note that this population has a high pro-
portional representation of women, and thus studies of this
sort have a positive bias to address this pressing concern
in this group who are normally excluded from surgical re-
search.10
There are several key findings that have implications for
a definitive trial:
1. We randomized before induction to allow the perfusion-
ist to set up the circuit in advance so as not to ‘‘waste’’The Journal of Thoracic and Caultrafiltration devices. Unexpectedly, we had a high per-
centage of cases excluded by the surgeon after randomi-
zation but before induction, unlike the trial of Luciani and
associates.7 Therefore, resources should be available to
allow randomization at the point of protamine adminis-
tration, preparing each patient as part of the MUF group
with splicing out of the filter if the randomization is to
control.
2. Inasmuch as the surgeon could not be blinded success-
fully, it is unnecessary to bind the tubing with tape. The
surgeon could still be kept blinded to hematocrit results
and instructed not to participate in transfusion decisions.
3. The intervention was successful (ie, 50% of the pump
balance removed in 15 minutes) in 59% of patients.
The target of this removal threshold was chosen on the
basis of the most common practice in the literature6; on
the basis of the current study, perhaps an additional
5 minutes should be considered to augment this.
4. This study was difficult to complete and expensive owing
to the complexity of the model and the need for careful
supervision with regard to compliance and blinding. It
would be greatly facilitated by educational videos to par-
ticipating teams demonstrating precise techniques of
MUF application and setup.
As expected, there was no statistically significant differ-
ence in transfusion rate in the 2 groups because the trial
was not powered for this. On the basis of the standard devi-
ations for the units of red cells administered, we can predict
that in a definitive trial, to test a hypothesis whereby this
technology decreased the exposure of patients to units of
red blood cells in the intervention group by 20% (0.6
units/patient [2.0 vs 2.6; SD, 1.7 units]), one would need
182 patients per group (alpha, .05; power, 80%).
The major limitation of this trial, as described above,
related to the impact of inadvertent withdrawal of patientsrdiovascular Surgery c Volume 139, Number 3 705
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be effectively addressed by changing the protocol in the
definitive trial. It is emphasized that this was a pilot trial
specifically designed to identify these methodologic
issues.
In summary, in a randomized controlled trial assessing the
feasibility of comparing MUF with sham in CPB, the anes-
thesiologists and the intensivists were successfully blinded
to the intervention and there was a high compliance rate
with the transfusion protocol. MUF successfully effected he-
moconcentration by decreasing the corrected pump prime,
but it is not clear whether this results in a decrease in the sub-
sequent exposure to blood products. It appeared that patients
undergoing MUF were more likely to require vasopressor
support after the intervention. It would be feasible, although
difficult, to address the question of the efficacy of MUF in
a larger randomized controlled trial. Such a trial would
have to include important safety measures regarding exces-
sive hypovolemia that may place the patients at risk to lower
postoperative cardiac output with the intervention, and this
information would be essential before considering universal
application of this technology.
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